Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) approved for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [1] . After being evaluated in CML patients as salvage therapy, dasatinib treatment was associated with a significantly higher and faster rate of molecular response in patients with newly diagnosed chronic-phase CML when compared with imatinib [2] . Therefore, current guidelines recommend dasatinib as 1 of 3 standard first-line TKI agents for treatment of patients with chronic-phase CML [3] .
In the setting of Ph+ALL, TKI therapy before allogeneic hematopoietic-cell transplant (HCT) has increased complete hematological response rates and 5-year overall patient survival [4] . Despite these improvements, HCT remains the treatment of choice for adults with Ph+ALL. The reported disease-free survival rate after allogeneic HCT is 27%-48% and tends to be higher when performed in first complete remission (CR1) [5] . However, about 30% of Ph+ALL patients who undergo HCT in CR1 eventually relapse [6] . In the last few years there has been considerable interest in the impact of TKI therapy, either prophylactically or preemptively, after molecular detection of BCR-ABL transcripts on the incidence of minimal residual disease, remission duration, and long-term outcomes in Ph+ALL patients who undergo allogeneic HCT [7] .
Adverse side effects of TKI therapy, including cytopenias, fluid retention, cutaneous eruptions, and digestive disorders, are well described [1] . In addition, recent reports that describe the development of viral infections in patients who received dasatinib prior to HCT, such as cytomegalovirus (CMV) infection, suggest a potential for immunosuppression and viral reactivation [8, 9] . However, the relationship between the occurrence of viral infections and post-HCT dasatinib use has not been evaluated.
In this study, we examined the potential association between dasatinib use post-HCT and CMV reactivation, after observing some patients who developed CMV reactivation and CMV disease after treatment with dasatinib in the absence of other usual risk factors for CMV reactivation.
METHODS

Study Patients
We assessed medical records of all patients with CML or Ph+ALL who underwent HCT at Dana-Farber Cancer Institute between January 2006 and December 2015. Data collected included patient's demographic information, underlying disease, conditioning regimens, graft type, donor and recipient relatedness, CMV serostatus, TKI (dasatinib, nilotinib, and imatinib) use and time of TKI exposure post-HCT, CMV reactivation characteristics and its treatment, acute and chronic graft-versus-host disease (GVHD) occurrence, and immunosuppressant use. Patients were prescribed TKI at the discretion of their treating clinician. Cytomegalovirus reactivation and disease were classified according to standard definitions [10] . Patients were followed until 1 April 2016 and monitored for CMV reactivation for 1 year after HCT. Dana-Farber's Office of Human Research Studies approved the study.
Statistical Analyses
Baseline characteristics were compared using 2-sided Fisher exact test or Wilcoxon rank-sum test, where appropriate. We used multivariate time-dependent Cox proportional hazards modeling to assess CMV risk post-HCT; a 2-sided P value ≤ .05 was considered statistically significant.
A total of 109 patients underwent HCT for treatment of CML or Ph+ALL during the study period. Cohort characteristics are shown in Table 1 . Dasatinib was used after HCT in 21 patients, including 5 for prevention and 16 for treatment of molecular relapse for a median of 75 days (range, 6-633). Patients received a median dasatinib dose of 100 mg/day (range, 70-140).
We identified 25 CMV events over a median follow-up of 1.7 years (see Supplementary Table 2 ). Twenty-three CMV events occurred by 1 year post-HCT. All CMV events occurred among 63 seropositive (CMV R+) patients. Twenty-two patients had CMV viremia and 3 had proven CMV disease, including 1 patient with CMV gastritis and 2 patients with CMV colitis. The median time from transplant to CMV reactivation was 56 days (range, 10-784). All 25 patients received antiviral treatment with valganciclovir, intravenous ganciclovir, or foscarnet. Patients remained viremic for a median time of 25 days (range, 3-59); the median CMV viral load at diagnosis was 1000 copies/mL (range, 154-13 224), and the median peak viral load was 4400 copies/mL (range, 154-33 925).
Among 13 CMV R+ patients who received dasatinib after HCT, we observed 8 (61.5%) CMV events; 17 (34%) events occurred among 50 CMV R+ patients who were not exposed to dasatinib post-HCT. The 1-year cumulative incidence of CMV events in dasatinib-exposed CMV R+ patients was 0.75 (95% confidence interval [CI], 0.33-0.99) vs 0.33 (95% CI, 0.23-0.48) in those unexposed. The median time from HCT to dasatinib start was 99 days (range, 64-376) and between dasatinib start Abbreviations: CMV, cytomegalovirus; GVHD, graft-versus-host disease; HCT, hematopoietic-cell transplantation; HLA, human leukocyte antigen. a CMV surveillance testing using CMV polymerase chain reaction was performed at every clinic visit in most patients. Patients were usually seen weekly through day +100; frequency of visits decreased in patients who were doing well to every 2 to 4 weeks until 1 year post-transplant.
and CMV reactivation was 85 days (range, 71-127). Four dasatinib-associated CMV events occurred more than 6 months post-HCT (range, day +158 to day +212) in patients off immunosuppression and without acute or chronic GVHD, including a patient with proven CMV colitis. We assessed several risk factors for CMV events in univariable Cox proportional hazards models (Supplementary Table  2 ). Acute GVHD grades II-IV and dasatinib use post-HCT were found to be associated with the primary outcome (P < .1). After controlling for time-dependent acute GVHD (adjusted hazard ratio [aHR], 2.05; 95% CI, 0.88-4.80), time-dependent dasatinib use after HCT remained an independent risk factor for CMV reactivation (aHR, 7.65; 95% CI, 1.84-31.7) in the first year post-transplantation (Supplementary Table  3 ). We found no impact of incident chronic GVHD or clinical relapse of Ph+ALL or CML on the risk of CMV events.
The use of other TKIs after HCT was also assessed. Seven (6.4%) patients received nilotinib and 9 (8.2%) patients received imatinib post-HCT. Two of 7 (28.5%) nilotinib-treated patients and 1 of 9 (11%) imatinib-treated patients had CMV events; however, all events occurred before exposure to these 2 TKIs, and no further association with CMV events could be explored.
DISCUSSION
We found that dasatinib use after HCT to prevent or preemptively treat molecular relapse of Philadelphia chromosome-positive hematological malignancies significantly increased the risk of CMV reactivation in the first year after transplant in CMVseropositive recipients, even after adjusting for acute GVHD in time-dependent Cox modeling. Several CMV events occurred 2 to 4 months after dasatinib exposure in patients who were off immunosuppression and without GVHD.
Since the introduction of TKIs, there has been interest in their effects on the immune system. In addition to BCR-ABL, dasatinib has been shown to suppress effector memory T-cell function through blockage of SRC and TEC family kinases, which in turn are involved with the regulation of the immune response and the modulation of immune cell subsets [11] . These effects can compromise key immune mechanisms responsible for preventing CMV reactivation. Therefore, previous studies have highlighted potential associations of dasatinib with different infections, including CMV [12, 13] . However, the majority have included patients treated with dasatinib before HCT as part of chemotherapy regimens among Ph+ALL patients, making it difficult to determine whether these episodes of infection are attributable to dasatinib's sole effect on the immune system. Although it has been proposed that imatinib could reduce CMV events, Travi and colleagues found a nonsignificant increased aHR of 1.6 (range, 0.7-3.4) of CMV reactivation post-HCT [14] . In the present study, after controlling for recipient CMV serostatus and acute grade II-IV acute GVHD, dasatinib use was an independent predictor for CMV reactivation.
Our study had limitations. First, the cohort's size did not allow the identification of additional predictors of CMV infection or construct more comprehensive multivariate models. Second, the number of patients who were exposed to other TKIs after HCT may have impaired our ability to detect an effect of imatinib or nilotinib on the potential risk of CMV reactivation.
With new strategies for treatment and prevention of hematological diseases, physicians should keep in mind the potential immunological mechanisms that may increase the risk of CMV reactivation and other opportunistic infections in patients who receive dasatinib as a post-HCT treatment therapy. Confirmation of this observation in other cohorts or in randomized studies is needed to further evaluate the infectious diseases risks of TKI use post-HCT. Pending confirmation of this association, it is prudent to closely monitor patients who receive dasatinib and other TKIs post-HCT for CMV reactivation.
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